A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

June 14, 2023

Study Completion Date

September 1, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Abatacept

Abatacept SC (125 mg) once weekly

DRUG

Adalimumab

Adalimumab SC (40 mg) once every 2 weeks

DRUG

Methotrexate

Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)

Trial Locations (75)

0

Local Institution - 0099, Córdoba

220

Local Institution - 0104, New Taipei City

402

Local Institution - 0095, Taichung

704

Local Institution - 0120, Tainan City

1428

Local Institution - 0022, Buenos Aires

Local Institution - 0023, Buenos Aires

1431

Local Institution - 0015, Buenos Aires

1642

Local Institution - 0014, San Isidro

1878

Local Institution - 0016, Quilmes

2019

Local Institution - 0072, Botany

2150

Local Institution - 0062, Paramatta

3079

Local Institution - 0105, Ivanhoe

3124

Local Institution - 0064, Camberwell

3220

Local Institution - 0065, Geelong

4031

Local Institution - 0049, Basel

4558

Local Institution - 0063, Maroochydore

5011

Local Institution - 0102, Woodville South

9007

Local Institution - 0052, Sankt Gallen

10117

Local Institution - 0059, Berlin

11201

NYU Langone Ambulatory Care Brooklyn Heights, Brooklyn

11850

Local Institution - 0006, Mexico City

12850

Local Institution - 0025, Prague

14080

Local Institution - 0008, Mexico City

15006

Local Institution - 0004, A Coruña

16635

Local Institution - 0031, Duncansville

20095

Local Institution - 0053, Hamburg

21502

Local Institution - 0058, Cumberland

21740

Local Institution - 0038, Hagerstown

27100

Local Institution - 0077, Pavia

28046

Local Institution - 0003, Madrid

28401

Local Institution - 0082, Wilmington

31000

Local Institution - 0009, Chihuahua City

31059

Local Institution - 0002, Toulouse

34295

Local Institution - 0001, Montpellier

38305

Local Institution - 0034, Jackson

39008

Local Institution - 0085, Santander

40447

Local Institution - 0096, Taichung

44650

Local Institution - 0017, Guadalajara

Local Institution - 0117, Guadalajara

53127

Local Institution - 0055, Bonn

53217

Local Institution - 0119, Milwaukee

55121

Local Institution - 0084, Eagan

67098

Local Institution - 0035, Strasbourg

75231

Local Institution - 0044, Dallas

76031

Local Institution - 0047, Rouen

78200

Local Institution - 0118, San Luis Potosí City

79106

Local Institution - 0091, Freiburg im Breisgau

80045

Local Institution - 0041, Aurora

82152

Local Institution - 0056, Planegg

83301

Local Institution - 0098, Kaohsiung Niao Sung Dist

90720

Local Institution - 0086, Los Alamitos

92835

Local Institution - 0036, Fullerton

95121

Local Institution - 0083, Catania

97070

Local Institution - 0005, Mérida

97239

Local Institution - 0127, Portland

1600035

Local Institution - 0010, Tokyo

07728

Local Institution - 0040, Freehold

C1015ABO

Local Institution - 0012, CABA

T4000

Local Institution - 0057, San Miguel de Tucumán

638 00

Local Institution - 0028, Brno

06156

Local Institution - 0078, Perugia

00168

Local Institution - 0100, Roma

457-8511

Local Institution - 0093, Nagoya

807-8556

Local Institution - 0079, Kitakyushu

0608648

Local Institution - 0110, Sapporo

980-8574

Local Institution - 0046, Sendai

857-1195

Local Institution - 0112, Sasebo

350-8550

Local Institution - 0090, Kawagoe

104-8560

Local Institution - 0089, Tokyo

87-100

Local Institution - 0020, Torun

85-168

Local Institution - 0124, Bydgoszcz

82-300

Local Institution - 0019, Elblag

WS11 5XY

Local Institution - 0111, Cannock

HU3 2JZ

Local Institution - 0060, Hull

SE1 9RT

Local Institution - 0114, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04909801 - A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter